## Core Concept
The question tests the understanding of monoamine oxidase inhibitors (MAOIs), specifically the distinction between selective MAO-B inhibitors and non-selective MAOIs. MAO-B inhibitors are a class of drugs used primarily in the treatment of Parkinson's disease. They work by selectively inhibiting the monoamine oxidase B enzyme, which is involved in the breakdown of dopamine in the brain.

## Why the Correct Answer is Right
The correct answer, , is a selective MAO-B inhibitor. This class of drugs, including , works by inhibiting the monoamine oxidase B (MAO-B) enzyme. This inhibition prevents the breakdown of dopamine, thereby increasing its availability in the brain, which is beneficial for patients with Parkinson's disease. The selectivity for MAO-B over MAO-A at therapeutic doses reduces the risk of hypertensive crises associated with non-selective MAOIs when patients consume tyramine-rich foods.

## Why Each Wrong Option is Incorrect
* **Option A:** is not a selective MAO-B inhibitor; it is a non-selective MAOI. Non-selective MAOIs inhibit both MAO-A and MAO-B enzymes, which can lead to dietary restrictions to avoid hypertensive crises.
* **Option B:** is not primarily recognized as a selective MAO-B inhibitor; its primary use and classification might differ.
* **Option D:** is not a selective MAO-B inhibitor; similar to option A, it might have a different mechanism or classification.

## Clinical Pearl / High-Yield Fact
A key clinical pearl is that selective MAO-B inhibitors like are preferred in the treatment of Parkinson's disease because they have a lower risk of causing hypertensive crises compared to non-selective MAOIs. This selectivity allows for a more targeted approach to increasing dopamine levels without the stringent dietary restrictions required for non-selective MAOIs.

## Correct Answer Line
**Correct Answer: .**